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Introduction 
Pilosebaceous Unit (PSU) 
The pilosebaceous unit (PSU) consists of a sebaceous 
gland (SG) and an associated hair follicle (Figure 1), 
[1]. Sebaceous glands secrete sebum, which coats 
the hairs and is released along the hair shaft onto the 
skin surface [2]. Most of the sebaceous lipids are 
synthesized de novo and consist of squalene, 
cholesterol, cholesterol esters, wax esters, and 
triglycerides [2]. Sebum functions as a hydrophobic 
coating to reduce transepidermal water loss (TEWL) 
and maintain skin moisture and smoothness [2].  
Abstract 
Skin is the largest peripheral endocrine organ and 
functions as a hormone target and endocrine gland. 
A cutaneous hypothalamus-pituitary-adrenal (HPA)-
like axis enables the skin to respond to stress and 
regulates its steroidogenic activity. The 
pilosebaceous unit is a site for production and 
metabolism of a number of steroid hormones, 
including stress and sex hormones. This is an 
overview of the important role that the cutaneous 
HPA-like-axis plays in the pathogenesis and 
treatment of inflammatory pilosebaceous disorders, 
including acne, rosacea, seborrheic dermatitis, and 
hidradenitis suppurativa. 
Abbreviations 
ACTH  adrenocorticotropic hormone 
C. albicans Candida albicans 
CRH corticotropin releasing hormone 
DHEAS dehydroepiandrosterone sulfate 
DHT dihydrotestosterone 
ER endoplasmic reticulum 
FFA free fatty acids 
FGFRs fibroblast growth factor receptors 
GRH gonadotropin releasing hormone 
HPA hypothalamus-pituitary-adrenal 
HS hidradenitis suppurativa 
IGF insulin-like growth factor 
IL interleukin 
MC5R melanocortin-5-receptors 
MSH melanocyte stimulating hormone 
mTORC1 mechanistic target of rapamycin complex 1 
NRS National Rosacea Society 
OCPs oral contraceptive pills 
P. acnes Propionibacterium acnes 
PGA physician global assessment 
POMC proopiomelanocortin 
PPARs peroxisome proliferator-activated receptors
PSU pilosebaceous unit 
SD seborrheic dermatitis 
SG sebaceous gland 
SHBG sex hormone binding globulin 
TEWL transepidermal water loss 
TLR2 toll-like receptor 2 
TNF tumor necrosis factor 
TRH thyrotropin releasing hormone 
UV ultraviolet 
VEGF vascular endothelial growth factor 
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Sebum also aids in transport of fat-soluble 
antioxidants to and from the skin surface [3] and 
protects the skin from ultraviolet (UV) irradiation [4]. 
Sebum production is regulated by both neural and 
endocrine controls. In vitro and animal studies 
suggest that SGs are regulated by androgen 
hormones, retinoids, melanocortins 
[adrenocorticotropic hormone (ACTH) and 
melanocyte stimulating hormone (MSH)], 
peroxisome proliferator-activated receptors (PPARs), 
and fibroblast growth factor receptors (FGFRs), [5]. 
Androgens and PSU 
Sebaceous glands express all enzymes necessary for 
de-novo steroidogenesis, as well as conversion of 
weaker androgens into more potent ones (Figure 2), 
[1, 6]. Dehydroepiandrosterone sulfate (DHEAS), a 
weak androgen, is converted to more potent 
androgens (testosterone and dihydrotestosterone 
(DHT)) within the SG [1]. Androgen receptors within 
the PSU respond to both testosterone and its more 
potent counterpart, DHT [7]. End organ receptor 
sensitivity within the PSU plays a major role in the 
function of androgens. Individuals with complete 
androgen insensitivity lack detectable sebum 
secretion and as a result, do not develop acne 
vulgaris [8]. Starting at age twenty, sebum secretion 
begins to decline by 23% per decade in men and 32% 
per decade in women [9], which parallels the decline 
in serum DHEAS levels [10]. 
Hepatic synthesis of insulin-like growth factor (IGF)-1 
in response to growth hormone release by the 
pituitary gland has a direct impact on SG function 
[11]. IGF-1 exerts its effects on the PSU via the IGF-
1/AKT/mTORC1/SREBP1 signaling pathway, which is 
responsible for androgen production and 
sebogenesis [12]. Insulin-like growth factor-1 
regulates androgen synthesis, androgen 
metabolism, and end organ androgen sensitivity 
[13]. Specifically, IGF-1 induces adrenal and gonadal 
androgen synthesis, promotes the expression of 5-α-
reductase, and thus increases conversion of 
testosterone to DHT [13, 14]. Insulin-like growth 
factor-1 also depletes FoxO1, an important negative 
regulator of androgen receptor transactivation, via 
AKT-mediated phosphorylation [13]. Furthermore, 
basal and suprabasal sebocytes express IGF-1 
receptor [15]. Insulin-like growth factor-1 [16] and 
androgens [17] both increase sebocyte SREBP1c 
expression, a key transcription factor in sebaceous 
lipogenesis. Insulin and IGF-1 activate the 
mechanistic target of rapamycin complex 1 
(mTORC1), which stimulates expression of 
peroxisome proliferator-activated receptor-γ and 
SREBP1c, leading to increased sebogenesis [12, 13].  
Figure 1. Normal pilosebaceous unit. 
The pilosebaceous unit consists of 
sebaceous gland and an associated 
hair follicle. The sebaceous gland 
function is regulated by androgens, 
retinoids, melanocortins, MSH, PPARs, 
and FGFRs. The sebaceous glands 
secrete an oily substance called sebum, 
which coats the hair and is released 
along the hair shaft onto the skin’s 
surface. The sebaceous lipids consist of 
squalene, cholesterol, cholesterol 
esters, wax esters, and triglycerides. 
These lipids provide hydrophobic 
coating and as a result help reduce 
trans epidermal water loss, increase 
ultraviolet protection, aid in 
antioxidant transport to and from skin’s 
surface, as well as maintain skin 
moisture and smoothness. 
Volume 26 Number 2| February 2020| 
26(2):1 
 
 
- 3 - 
Dermatology Online Journal  ||  Review 
Systemic and cutaneous stress response systems 
Systemic stress leads to hypothalamic release of 
corticotropin releasing hormone (CRH), which 
activates CRH receptors in the pituitary gland, 
leading to synthesis and release of 
proopiomelanocortin (POMC)-derived peptides 
(MSH and ACTH), (Figure 3A), [18]. 
Adrenocorticotropic hormone enters the peripheral 
 
Figure 2 Androgens and the pilosebaceous unit. Sebaceous 
glands not only contain enzymes needed for de-novo 
steroidogenesis, but also enzymes needed for the conversion of 
weaker androgens into more potent ones. Growth hormone (not 
pictured) is released by the pituitary gland and stimulates IGF-1 
synthesis in the liver. Subsequently, IGF-1 induces adrenal and 
gonadal production of androgens. In the skin, IGF-1 exerts its 
effects on the sebaceous unit via the IGF-1/AKT/mTORC1/SREBP1 
signaling pathway, which affects androgen and sebum 
production, androgen metabolism, and end organ androgen 
sensitivity. Specifically, IGF-1 promotes the expression of enzyme 
5-α-reductase, increasing the conversion of testosterone to DHT. 
Additionally, it increases sebogenesis and end-organ androgen 
receptor sensitivity. IGF1R, insulin-like growth factor-1 receptor; 
5αR, 5-α-reductase. 
 
Figure 3. Systemic stress response system (left) compared to 
cutaneous stress response (right). 
Systemic stress response system (left) In response to systemic 
stress, hypothalamus releases CRH, which subsequently activates 
CRH receptors in the pituitary gland, leading to synthesis and 
release of POMC-derived peptides, ACTH and MSH, by the 
pituitary gland. Subsequently, ACTH enters peripheral circulation 
and stimulates rapid synthesis and release of glucocorticoid 
hormones, including cortisol (stress response hormone), by the 
adrenal glands. MSH stimulates sebum synthesis by the 
sebaceous glands. The secretion of cortisol is controlled via 
negative feedback mechanisms, in which plasma cortisol inhibits 
CRH release by the hypothalamus and ACTH release by the 
pituitary, as demonstrated in this figure. (For other negative 
feedback mechanisms, see text). In response to systemic stress, 
the immune system generates pro-inflammatory cytokines, such 
as IL-1, IL-6, and tumor necrosis factor (TNF), which also stimulate 
the HPA-axis to increase cortisol production. When cortisol is 
produced, it exerts its anti-inflammatory properties by inhibiting 
IL-1, IL-6, and TNFα.  
Cutaneous stress response (right) In response to external 
stressors, including pro-inflammatory cytokines IL-1, IL-6, and 
TNF, the skin stress response system involves only locally 
produced CRH and POMC. The locally produced CRH stimulates 
the CRH receptors, resulting in inhibition of sebocyte 
proliferation, increased sebum production, and enhanced 
expression of Δ5-3β-hydroxysteroid dehydrogenase, an enzyme 
responsible for androgen activation. Furthermore, CRH leads to 
local production of POMC-derived peptides, ACTH and MSH, 
which stimulate the MC receptors to increase sebum production. 
5-3β-HSD, Δ5-3β-hydroxysteroid dehydrogenase; IL-1, 
interleukin-1; IL-6, interleukin-6; MC-Receptor, melanocortin 
receptor; POMC, propiomelanocortin; MSH, α-melanocyte 
stimulating hormone.
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circulation to stimulate adrenal DHEAS and cortisol 
production [19]. In addition, cortisol is produced by 
the hair follicles [20]. Cortisol is a stress response 
hormone [21] and has versatile anti-inflammatory 
properties [18]. Its secretion is controlled via three 
major negative feedback mechanisms: 1) by plasma 
cortisol [22], which inhibits CRH and ACTH secretion 
in hypothalamus and pituitary, 2) by pulsatile 
secretion of ACTH [23], which is dependent on 
circadian rhythm and peaks around 6-8am on a 
typical sleep cycle, and 3) by emotional and physical 
stress [24], which stimulate CRH secretion from sites 
other than hypothalamus, including the skin. Cortisol 
in turn terminates the stress response and attenuates 
CRH and POMC peptide production, closing the 
negative feedback loop [18]. Pro-inflammatory 
cytokines, such as IL-1, IL-6, and tumor necrosis 
factor (TNF) stimulate the HPA-axis [18] leading to 
cortisol increase. 
The SG is analogous to the “brain of the skin” [25] and 
provides the peripheral equivalent of the HPA-axis 
[26]. The skin responds to and synthesizes stress 
mediators such as CRH, ACTH, cortisol, and 
catecholamines [26]. In contrast to the systemic 
stress response system, the skin stress response 
involves only locally produced CRH and POMC 
synthesized in response to external stressors, 
including proinflammatory cytokines [18, 26]. 
Corticotropin releasing hormoneis the most 
proximal hormone in the cutaneous HPA-like axis, 
whereas the CRH-binding protein and corticotrophin 
receptors act as downstream regulators (Figure 3B). 
Corticotropin releasing hormone inhibits sebocyte 
proliferation, induces production of sebaceous 
lipids, and enhances expression of Δ5-3β-
hydroxysteroid dehydrogenase, an enzyme 
responsible for androgen activation [25, 27]. Thus, 
CRH-stimulation may play a role in the development 
of acne, rosacea, and other skin disorders associated 
with alterations in lipid synthesis by SG [25, 27].  
Melanocortins (ACTH and α-MSH) stimulate 
sebaceous squalene production by sebocytes 
derived from normal facial skin [28]. Melanocortin-5-
receptors (MC5-R) are found in SG, and regulate 
sebaceous function [29]. Rodent studies have 
confirmed that melanocortins increase sebum 
production and that targeted disruption of MC5-R 
leads to decreased sebum production [30]. During 
stress, ACTH acts on SG to mediate steroidogenesis 
and sebum production [29]. Melanocortins mediate 
SG hormonal responses to stress and present a link 
between stress and acne exacerbation [29]. The 
cutaneous HPA-like axis involves the intricate 
interaction between the PSU and its associated 
steroid hormones and plays an important role in the 
pathogeneses and treatment of acne vulgaris, 
rosacea, seborrheic dermatitis, and hidradenitis 
suppurativa. 
 
Discussion 
Cutaneous HPA-axis and inflammatory pilosebaceous 
dermatoses 
Acne vulgaris 
Acne vulgaris is a chronic inflammatory disorder of 
the PSU characterized by comedones, inflammatory 
papules and pustules, and occasionally nodulocystic 
lesions on the sebaceous-rich areas including the 
face, scalp, chest, and back. The pathogenesis of 
acne is multifactorial and includes increased 
follicular corneocyte adhesion, sebum production, 
and perifollicular inflammation promoted by 
Propionibacterium acnes (P. acnes), (Figure 4B), [31]. 
Cortisol and acne 
Psychological stress leads to various hormonal 
changes, including increases in serum CRH and 
cortisol levels [32]. Cortisol is produced by adrenal 
glands and hair follicles after they are stimulated by 
CRH [20]. Although studies on direct effects of 
elevated serum cortisol on acne are lacking, acne 
exacerbation is associated with both acute and 
chronic psychological stress [33, 34]. Emotional 
stress induced by an academic examination led to a 
significant increase in pustule count compared to 
counts three weeks prior to the examination and two 
weeks after examination results were released 
(P<0.01, counts not specified), [34]. This acne 
exacerbation was associated with an increase in skin 
surface free fatty acid (P<0.005), [34]. Overall, 
sebocytes can be stimulated by stress reactants, such 
as CRH, to increase production of sebum and 
proinflammatory peptides, resulting in acne 
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formation and exacerbation [35, 36]. Since cortisol is 
a stress hormone and acne is believed to worsen 
intimes of stress, it is likely that cortisol plays a role in 
acne development and exacerbation. However, the 
mechanism by which cortisol may be associated with 
acne is unclear and studies evaluating serum cortisol 
levels in individuals with acne are necessary. 
Androgens and acne 
During puberty, sex hormones trigger SG activation, 
leading to excess sebum production [25], a key factor 
in follicular adhesion and acne vulgaris 
pathogenesis. Androgens bind to sebocytes to 
stimulate sebogenesis [37] providing an ideal 
environment for P. acnes proliferation [31]. 
Dehydroepiandrosterone sulfate stimulates sebum 
production in men and women, as well as acne 
development in prepubertal girls [38]. Elevated 
serum androgen levels are associated with severe 
nodular acne in both sexes. However, although 
androgens enhance sebogenesis, they are not the 
only endocrine stimulus for acne development. 
Individuals with mild to moderate acne may have 
normal serum androgen levels, highlighting the 
influence of end-organ receptor sensitivity [39]. Vora 
et al. showed that serum IGF-1 levels correlate with 
facial sebum secretion rate in individuals with acne 
vulgaris [40]. Acne severity correlates with serum 
levels of IGF-1, but not with serum androgens, which 
persist at high levels after puberty despite the 
decrease in acne after puberty [41, 42]. Interestingly, 
patients with Laron syndrome who have a congenital 
IGF-1 deficiency exhibit functional androgen 
receptors but do not develop acne, unless 
supplemented with high doses of recombinant IGF-
Figure 4. The role of cutaneous HPA-like axis and steroid 
hormones on the pilosebaceous unit are depicted for: A) 
normal skin; representation of normal pilosebaceous 
unit and sebum. B) Acne vulgaris; psychological stress 
leads to various changes, including increase in serum 
CRH, CRH-R, CRH-BP, MC1R, and cortisol levels. Sebocytes 
are stimulated by stress reactants, such as CRH, to 
increase production of sebum and proinflammatory 
peptides, resulting in acne formation and exacerbation. 
Androgens bind to sebocytes and stimulate an increase 
in sebum synthesis providing an ideal environment for P. 
acnes proliferation. The pathogenesis of acne is 
multifactorial and includes increased follicular 
corneocyte adhesion, sebum production, and 
perifollicular inflammation promoted by 
Propionibacterium acnes (P. acnes), as demonstrated 
here. C) Rosacea; UV radiation leads to generation of 
reactive oxygen species (ROS) in the skin, which damage 
blood vessels and dermal matrix. Additionally, UV 
radiation stimulates the cutaneous HPA-axis to increase 
CRH, POMC, ACTH, and cortisol production. CRH in turn
activates mast cells, resulting in increased pro-inflammatory cytokines IL-6 and IL-8 (manifests as facial erythema), and histamine release 
causing vasodilation (manifests as skin flushing and warmth). The increase in vascular endothelial growth factor (VGEF) is responsible for 
angiogenesis in rosacea. These dermal changes are associated with altered sebaceous fatty acid composition. D) Seborrheic dermatitis; 
Seborrheic dermatitis is associated with Malassezia overgrowth, which leads to alteration of sebaceous fatty acid composition, rather 
than the total quantity of sebum. Specifically, the Malassezia lipases and phosphatases hydrolyze sebum, which results in irritating FFA 
formation and skin inflammation. This manifests as erythematous patches and plaques with greasy scale affecting SG rich locations. E) 
Hidradenitis suppurativa; In HS, androgens induce hyperkeratosis, which leads to follicular occlusion by the keratin plug. This follicular 
occlusion ultimately leads to follicular rupture, inflammation, and secondary infection. Although some individuals with HS may have 
elevated androgen levels, not all do. It is hypothesized that increased peripheral receptor sensitivity to sex hormones, rather than total 
serum sex hormone levels, contributes to HS. IGF-1 is likely responsible for this increased androgen receptor sensitivity. HS is also 
associated with increased sebaceous gland atrophy. 5-3β-HSD, Δ5-3β-hydroxysteroid dehydrogenase; CRH-BP, CRH-binding protein; 
CRH-R, CRH-receptor; MC1R, melanocortin-1-receptors; ROS, reactive oxygen species. 
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1, which suggests that IGF-1 and androgen 
interaction are needed for acne development [43]. 
Estrogens and acne 
Estrogens suppress androgen production and SG 
size and function [41], which in turn improves acne. 
A higher dose of estrogen is needed to suppress SG 
function than ovulation [44]. Estrogens are believed 
to oppose the effects of androgens within SG by 
reducing sebum synthesis, inhibiting gonadal tissue 
androgen production, and regulating genes 
involved in SG growth [44]. 
Acne therapies and their cutaneous targets 
Various hormonal therapies have been used for acne 
treatment. Anti-androgens inhibit the ovarian and 
adrenal androgen production, as well as androgen-
metabolizing enzymes in the PSU [44]. Androgen 
receptor blockers include spironolactone, 
cyproterone acetate, and flutamide. Spironolactone 
inhibits sebogenesis by blocking androgen receptor 
function and androgen production by inhibiting 5-α-
reductase [45, 46]. Spironolactone is a commonly 
used hormone-modulating therapy for adult female 
acne. Most patients using spironolactone experience 
improvement in their acne within three months [45]. 
Cyproterone acetate is an androgen receptor blocker 
that competes with androgens for its receptor [47]. 
In Europe, cyproterone acetate is combined with 
ethynyl estradiol into an oral contraceptive that is 
approved for acne treatment. Generally, oral 
contraceptive pills (OCPs) reduce ovarian androgen 
production, as well as sebum production [44]. 
Combined OCPs contain progesterone and estrogen; 
the latter increases synthesis of sex hormone binding 
globulin (SHBG) which binds to and reduces the level 
of free circulating testosterone [48]. For this reason, 
combined OCPs are more effective than 
progesterone-only therapies in treating acne [48]. 
Isotretinoin (13-cis-retinoic acid) is an oral retinoid 
and the most effective therapy for severe, 
recalcitrant acne [49]. Isotretinoin decreases the skin 
androgen receptor expression and suppresses DHT 
production [50] resulting in reduced sebogenesis 
and the overall SG size [51]. Additionally, isotretinoin 
induces sebocyte apoptosis [52, 53]. Furthermore,  
isotretinoin reduces serum levels of pituitary 
hormones [54] and hepatic synthesis of IGF-1 [55]. 
Rosacea 
Rosacea is a common chronic inflammatory skin 
disease consisting of several subtypes that are 
characterized by persistent centrofacial erythema 
with periods of trigger specific intensifications and 
facial phymatous changes [56, 57]. Facial flushing, 
telangiectasias, inflammatory papules and pustules, 
facial burning/stinging sensation, skin dryness, 
edema, and ocular manifestations are characteristics 
of rosacea [58]. Although its pathogenesis is poorly 
understood, the key contributing mechanisms 
include climatic exposures, vascular dysfunction, 
PSU abnormalities, matrix degeneration, microbial 
overgrowth, and emotional and physical stressors 
[59, 60]. TRPV1 are cell receptors in the skin that are 
activated by rosacea triggers such as spicy food, 
heat, and alcohol and are associated with 
neurovascular dysregulation in rosacea [61]. 
Furthermore, these triggers cause misfolded protein 
accumulation in the endoplasmic reticulum (ER) to 
cause ER stress [62], which leads to increased 
cathelicidin production (antimicrobial peptide) and 
elevated proinflammatory and angiogenic signaling, 
all of which are pathogenic factors of rosacea [62]. 
The papulopustular rosacea (PPR) subtype is 
associated with altered sebaceous fatty acid 
composition, with normal total sebaceous fatty acid 
quantity. Altered sebaceous lipid composition is 
likely responsible for the skin barrier dysfunction in 
rosacea [63]. Demodex mites are a normal part of skin 
microbiome and abundant within the PSU on the 
face. However, individuals with rosacea tend to have 
significantly higher numbers of Demodex mites 
compared to healthy controls [64]. 
Cortisol and rosacea 
UV radiation stimulates the cutaneous HPA-axis to 
increase the production of CRH, POMC, ACTH, and 
cortisol (Figure 4C), [65]. Corticotropin releasing 
hormone activates mast cells leading to increased 
levels of proinflammatory cytokines IL-6 and IL-8, 
which manifests as facial erythema [66]. Mast cells 
also release histamine to cause vasodilation [66], 
which manifests clinically as skin flushing and 
warmth. Disturbance of corticosteroid homeostasis 
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also plays a major role in manifestation of rosacea 
[67]. Emotional stress activates the HPA-axis to 
increase cortisol release, which activates 
inflammatory pathways and impairs the skin barrier 
function [68]. In a survey conducted by the National 
Rosacea Society (NRS), emotional stress was reported 
as one of the most common rosacea triggers, 
affecting 79% of respondents [69]. In a similar survey 
by the NRS, 69% of individuals with rosacea reported 
that emotional stress was associated with monthly 
rosacea exacerbation [69]. Drake et al. reported that 
67% of patients can reduce rosacea exacerbations by 
focusing on stress reduction alone [69]. This survey 
did not differentiate between the different subtypes 
of rosacea. The mechanism for how emotional stress 
causes vasodilation and flushing remains unclear 
and may relate to histamine release as a result of 
elevated CRH. 
Androgens and rosacea 
Schmidt et al. reported no difference in androgen 
and estrogen receptor distribution or receptor levels 
between rosacea-affected skin and normal skin of 
the same patients [70]. Additionally, serum levels of 
sex steroids, androgen and estrogen, were within 
normal range. These findings suggest that sex 
steroid receptor distribution and serum hormone 
levels may not be involved in rosacea pathogenesis. 
The role of peripheral receptor sensitivity also 
remains unknown. 
Estrogen and rosacea 
Zaun et al. reported that corticosteroid mediated 
side effects on the skin, such as telangiectasias, 
rosacea, and striae are potentiated by estrogens [71]. 
Estrogen regulates the production of vascular 
endothelial growth factor (VEGF), which is 
responsible for angiogenesis [72]. VEGF promotes 
vascular leak and permeability and is sometimes 
referred to as the “vascular permeability factor” [73]. 
Notably, there is some evidence suggesting that 
estrogen alters the vaginal microbiome [74]. Its role 
in altering the facial skin microbiome, including 
Demodex, remains unclear.  
Rosacea management 
The first line management of rosacea includes 
avoidance of stressors, such as sun exposure, and 
utilizing adequate sun protection and moisturizing 
measures. Meditation and yoga are believed to act 
on the HPA-axis leading to reduced cortisol level [68] 
and are therefore recommended for emotional stress 
reduction. Unlike acne, hormonal therapy is not a 
component of rosacea treatment. 
Isotretinoin is a commonly used therapy for 
recalcitrant and inflammatory rosacea [51]. As 
mentioned previously, isotretinoin decreases the 
skin androgen receptor levels and suppresses DHT 
production [50], resulting in reduced sebogenesis 
and SG size [51]. Additionally, isotretinoin reduces 
facial cutaneous blood flow [51]. In a study among 22 
patients with treatment resistant rosacea, 10mg of 
isotretinoin daily for four months led to a significant 
decrease in inflammatory papules, pustules, 
erythema, and telangiectasia [75]. As mentioned 
previously, sebocytes produce abundant amounts of 
cathelicidin, an antimicrobial peptide and crucial ER-
stress induced effector of rosacea pathogenesis [76]. 
Isotretinoin causes sebocyte apoptosis, resulting in 
decreased production of sebum and cathelicidin 
[77]. 
Topical ivermectin 1% cream is an approved rosacea 
therapy that has dual anti-inflammatory and 
antiparasitic properties [78]. It leads to a reduction of 
Demodex mites in the skin and reduces the 
expression of proinflammatory cytokines, including 
IL-8, leading to improvement in clinical signs of 
rosacea [78].  
Seborrheic dermatitis 
Seborrheic dermatitis (SD) is an inflammatory 
condition characterized by both poorly and sharply 
demarcated, pink to erythematous patches and 
plaques with greasy scale affecting SG rich locations, 
such as the scalp, ears, face, and chest. The etiology 
is not completely understood but is considered to be 
associated with Malassezia overgrowth [79] and 
metabolism of sebaceous lipids, leading to altered 
sebaceous fatty acid composition, rather than the 
total quantity of sebum (Figure 4D), [80]. Lipases 
and phosphatases of Malassezia hydrolyze 
sebaceous lipids, breaking down triglycerides into 
free fatty acids (FFA), [80]. Certain FFA byproducts, 
such as oleic acid, cause skin irritation and a 
subsequent inflammatory response that is seen in SD 
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[80]. FFAs, such as palmitic and oleic acid, are also 
danger signals that stimulate toll-like receptor 2 
(TLR2), which activates the NLRP3 inflammasome 
[81]. Thus, isotretinoin-mediated sebum suppression 
may suppress sebaceous lipid-mediated 
proinflammatory effects. 
Cortisol and seborrheic dermatitis 
Misery et al. conducted a prospective survey study 
among 82 subjects with SD [82]. The majority 
reported stress as the main trigger of their disease 
[82]. However, our search did not result in any studies 
on the relationship between cortisol and SD. Future 
studies on this topic are needed. 
Androgens and seborrheic dermatitis 
No specific association between androgens and SD 
has been identified. However, SD begins at puberty 
and is more common in men than women 
suggesting that androgens may be implicated in SD 
pathogenesis [83]. Furthermore, seborrheic 
dermatitis may coincide with acne, supporting the 
idea that it is associated with oily skin [83] and that 
androgens may be the contributing factor. 
Estrogen and seborrheic dermatitis 
There is no evidence directly linking estrogen to SD. 
However, emerging evidence reveals that estrogen 
may affect the fungal microbiome (mycobiome), 
[84]. A study on castrated rats showed that those 
treated with an intravaginal estrogen challenge are 
susceptible to Candida albicans (C. albicans) 
colonization, whereas untreated rats remained 
resistant to yeast colonization [85]. Estrogen is 
considered to be one of the main factors influencing 
the pathogenicity of C. albicans in the vaginal 
environment [86, 87]. Although studies on estrogen 
and Malassezia are lacking, these data raise the 
possibility that estrogen may alter the skin 
mycobiome and contribute to SD development. 
Seborrheic dermatitis management  
Although hormonal therapy is not a component of 
SD management, isotretinoin affects the 
steroidogenesis pathway, as described in previous 
sections. In doing so, isotretinoin leads to decreased 
sebum production. Although altered sebaceous 
profile is the culprit for SD development rather than 
increased sebogenesis, isotretinoin is an effective 
treatment of refractory seborrhea and SD affecting 
the face and scalp [88]. In a randomized comparative 
trial involving 45 adults with refractory seborrhea or 
SD, patients who received isotretinoin (10mg every 
other day for six months) had significantly greater 
sebum reduction than subjects who received 
antiseborrheic topical therapy (shampoo for the 
scalp and soap for the face for six months), [88]. 
Patient opinion, investigator evaluation, and quality 
of life assessments improved in both groups. This 
study demonstrated that isotretinoin might be an 
effective alternative for SD treatment in individuals 
resistant to standard therapies. Further studies are 
needed to determine the exact mechanism by which 
isotretinoin improves SD. 
Hidradenitis suppurativa (HS) 
Hidradenitis suppurativa (HS) is a chronic, painful, 
and debilitating inflammatory skin condition that 
affects apocrine gland bearing areas, such as the 
axilla, inframammary folds, and groin [89]. The 
characteristic findings are painful nodules, sinus 
tracts, and scaring [90, 91]. HS typically develops 
after puberty [89]. Women are more prone to HS than 
men. However, men typically have a more severe 
form of HS [92]. Pathogenesis of HS remains 
controversial. It was long thought that the condition 
results from apocrine gland abnormality [91], but 
emerging evidence suggests that follicular structural 
fragility with subsequent aberrant adaptive 
immunity plays a major role [93]. IL-12, IL-23, and TNF 
are strongly implicated in HS pathogenesis [94, 95]. 
Furthermore, HS is associated with metabolic 
syndrome [96] and inflammatory bowel disease 
(Crohn disease), [96-98], suggesting a chronic 
inflammatory state. 
Cortisol and hidradenitis suppurativa 
There is currently no evidence linking psychological 
stress or cortisol level to the development of HS. 
Androgens and hidradenitis suppurativa 
HS flares are associated with the menstrual cycle and 
acne vulgaris, thus sex hormones likely play a role in 
HS pathogenesis [90, 99]. Androgens may contribute 
to HS pathogenesis as suggested by pre-menstrual 
flare-ups and symptom improvement during 
pregnancy [91, 100]. Follicular occlusion secondary 
to hyperkeratosis is an inciting event in HS and is  
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induced by androgens (Figure 4E), [101, 102]. 
However, in a systematic review of 59 studies, Riis et 
al. concluded that individuals with HS did not have 
elevated serum sex hormones levels [90]. Similarly, 
Harrison et al. enrolled 13 women with premenstrual 
HS flares and nine healthy controls to study the 
downstream hormonal response to stimulation by 
gonadotropin releasing hormone (GRH), (200 
micrograms) and thyrotropin releasing hormone 
(TRH), (200 micrograms), [100]. Serum levels of 
various hormones were measured at baseline and 10, 
20, and 60 minutes after challenge. There were no 
significant differences in the levels of estrogen, 
progesterone, total testosterone, and DHEAS at any 
time point between the two cohorts. Despite being 
an androgen-driven disorder, elevated total serum 
testosterone level is not the root cause. Increased 
target organ conversion of androgens to active 
metabolites likely contributes to HS pathogenesis 
[100]. 
Furthermore, it has been theorized that increased 
peripheral receptor sensitivity to sex hormones, 
rather than total serum sex hormone levels, 
contributes to HS. IGF-1 is likely responsible for this  
increased androgen receptor sensitivity. Specifically, 
high glycemic load and high dairy consumption, as is 
seen in a Western diet, lead to increased hepatic 
synthesis of IGF-1 and a resulting increase in 
androgen receptor exposure to circulating androgen 
hormones [103, 104]. Diets that limit dairy and high 
glycemic index foods are believed to prevent HS 
progression [105]. 
Estrogen and HS 
Serum estrogen regulates CRH function and acts on 
estrogen receptors within SG to suppresses SG 
activity [6]. There is no difference in the number of 
estrogen receptors found in apocrine glands in skin 
biopsies of individuals with HS compared with 
healthy skin [6]. However, HS is rare in menopausal 
women correlating with decline of estrogen levels, 
but the exact relationship between estrogen and HS 
has yet to be determined [6, 90]. 
HS management 
Spironolactone has provided HS relief in some 
individuals. In a retrospective, single center 
electronic database review study in Australia, 20 
women with HS who were treated with 
Table 1. Summary of inflammatory pilosebaceous dermatoses management. 
Disease  Management  Mechanism of action
Acne vulgaris  Spironolactone 
 
Inhibits 5-α-reductase  
Blocks androgen receptor function  
Cyproterone acetate Competitive inhibitor of androgen receptor 
Flutamide  Androgen receptor blocker 
Combined oral contraceptive 
pills  
Anti-androgenic  
(Increases SHBG and reduces free circulating androgens) 
Isotretinoin (13-cis-retinoic acid) Reduces skin androgen receptor expression  
Suppresses DHT production 
Induces sebocyte apoptosis 
Reduces serum levels of pituitary hormones  
Reduces hepatic synthesis of IGF-1 
Rosacea  Isotretinoin Reduces skin androgen receptor expression  
Suppresses DHT production 
Induces sebocyte apoptosis  
Reduces facial cutaneous blood flow 
Seborrheic dermatitis  Isotretinoin Reduces sebum production  
(Exact mechanism in SD unknown)  
Hidradenitis 
suppurativa  
Spironolactone Inhibits 5-α-reductase  
Blocks androgen receptor function 
Finasteride Blocks conversion of testosterone to DHT 
Reduces sensitivity of PSU to androgen stimulation
Combined oral contraceptive 
pills  
Anti-androgenic  
(Increases SHBG and reduces free circulating androgens)
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spironolactone showed significant improvement in 
disease severity measured by Physical Global 
Assessment (PGA). The authors suggested that 
spironolactone should be first-line therapy in mild to 
moderate HS [106]. However, the quality of this study 
is limited by small sample size, retrospective design, 
and single center data. Larger and better-designed 
studies are needed to evaluate the efficacy and 
safety of spironolactone as a treatment for women 
with HS. 
Finasteride exerts its anti-androgen effects by both 
blocking the conversion of testosterone to DHT and 
decreasing sensitivity of the PSU to androgen 
stimulation [107]. Finasteride may be a helpful 
therapy for HS and has a favorable safety profile 
[107]. In a case series of three pediatric patients with 
HS, finasteride reduced the frequency and severity of 
HS flares and caused no significant side effects [108]. 
Among seven adults with HS, six achieved significant 
improvement and three achieved complete healing 
of HS lesions [109]. Finasteride was well tolerated; 
one subject experienced generalized pruritus 
without a rash, whereas two female subjects 
reported breast enlargement [109]. Owing to risk of 
teratogenicity (Pregnancy Category X), reliable 
contraception is needed if finasteride is used in 
women of childbearing age. 
Oral contraceptives have been used to treat HS. 
When used over a 12-month period in women with 
HS, ethinyloestradiol /cyproterone acetate 50mg 
and ethinyloestradiol 50 micrograms/norgestrel 500  
micrograms both significantly reduced active 
circulating androgens and increased SHBG [110]. 
Additionally, HS cleared completely in 29% of 
subjects. These results suggest that anti-androgen 
therapy is beneficial in treating HS. 
 
Conclusion 
The cutaneous HPA-axis responds to endogenous 
and exogenous stressors in order to maintain local 
homeostasis. Corticotropin releasing hormone, 
ACTH, MSH, and cytokines are implicated in the 
regulation of the cutaneous HPA-axis and local 
steroidogenesis. Cutaneous HPA-axis dysregulation 
is involved in the development of inflammatory 
pilosebaceous disorders, including acne, rosacea, 
and HS. The role of steroid hormones and seborrheic 
dermatitis is least well characterized of these 
diseases. Additional studies are needed on the skin 
stress response system and its contribution to the 
development of inflammatory dermatoses. Steroid 
hormones play a role in inflammatory dermatoses 
and targeting cutaneous steroidogenic activity may 
be helpful in uncovering new therapeutic strategies 
(Table 1). 
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